About Atossa Therapeutics, Inc.
https://www.atossatherapeutics.comAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
CEO
Steven C. Quay FCAP,
Compensation Summary
(Year 2015)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2018-04-20 | Reverse | 1:12 |
| 2016-08-26 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:9.2M
Value:$5.34M
VANGUARD GROUP INC
Shares:6.08M
Value:$3.53M
AMERIPRISE FINANCIAL INC
Shares:2.95M
Value:$1.71M
Summary
Showing Top 3 of 78
About Atossa Therapeutics, Inc.
https://www.atossatherapeutics.comAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $9.25M ▲ | $-8.69M ▼ | 0% | $-0.07 ▼ | $-8.69M ▲ |
| Q2-2025 | $0 | $9.04M ▲ | $-8.42M ▼ | 0% | $-0.07 ▼ | $-9.04M ▼ |
| Q1-2025 | $0 | $7.41M ▲ | $-6.72M ▼ | 0% | $-0.05 ▼ | $-7.41M ▼ |
| Q4-2024 | $0 | $7.15M ▲ | $-6.35M ▲ | 0% | $-0.05 ▲ | $-7.15M ▼ |
| Q3-2024 | $0 | $6.38M | $-7.23M | 0% | $-0.06 | $-6.38M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $51.84M ▼ | $58.01M ▼ | $8.22M ▲ | $49.79M ▼ |
| Q2-2025 | $57.86M ▼ | $64.52M ▼ | $6.82M ▲ | $57.7M ▼ |
| Q1-2025 | $65.12M ▼ | $70.75M ▼ | $5.42M ▲ | $65.32M ▼ |
| Q4-2024 | $71.08M ▼ | $76.44M ▼ | $4.97M ▼ | $71.48M ▼ |
| Q3-2024 | $74.77M | $79.48M | $5.8M | $73.68M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.69M ▼ | $-6M ▲ | $-7K ▼ | $0 | $-6.01M ▲ | $-6.01M ▲ |
| Q2-2025 | $-8.42M ▼ | $-7.26M ▼ | $0 ▲ | $0 | $-7.26M ▼ | $-7.26M ▼ |
| Q1-2025 | $-6.72M ▼ | $-5.96M ▲ | $-9K ▼ | $0 ▼ | $-5.97M ▼ | $-5.97M ▲ |
| Q4-2024 | $-6.35M ▲ | $-7.05M ▼ | $0 ▲ | $3.37M ▲ | $-3.68M ▲ | $-7.05M ▼ |
| Q3-2024 | $-7.23M | $-4.75M | $-10K | $0 | $-4.76M | $-4.76M |
CEO
Steven C. Quay FCAP,
Compensation Summary
(Year 2015)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2018-04-20 | Reverse | 1:12 |
| 2016-08-26 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:9.2M
Value:$5.34M
VANGUARD GROUP INC
Shares:6.08M
Value:$3.53M
AMERIPRISE FINANCIAL INC
Shares:2.95M
Value:$1.71M
Summary
Showing Top 3 of 78